Literature DB >> 30308255

PAMAM dendrimers: blood-brain barrier transport and neuronal uptake after focal brain ischemia.

Sofia D Santos1, Miguel Xavier1, Diana M Leite1, Débora A Moreira1, Beatriz Custódio1, Marília Torrado1, Rita Castro2, Victoria Leiro1, João Rodrigues2, Helena Tomás2, Ana P Pêgo3.   

Abstract

Drug delivery to the central nervous system is restricted by the blood-brain barrier (BBB). However, with the onset of stroke, the BBB becomes leaky, providing a window of opportunity to passively target the brain. Here, cationic poly(amido amine) (PAMAM) dendrimers of different generations were functionalized with poly(ethylene glycol) (PEG) to reduce cytotoxicity and prolong blood circulation half-life, aiming for a safe in vivo drug delivery system in a stroke scenario. Rhodamine B isothiocyanate (RITC) was covalently tethered to the dendrimer backbone and used as a small surrogate drug as well as for tracking purposes. The biocompatibility of PAMAM was markedly increased by PEGylation as a function of dendrimer generation and degree of functionalization. The PEGylated RITC-modified dendrimers did not affect the integrity of an in vitro BBB model. Additionally, the functionalized dendrimers remained safe when in contact with the bEnd.3 cells and rat primary astrocytes composing the in vitro BBB model after hypoxia induced by oxygen-glucose deprivation. Modification with PEG also decreased the interaction and uptake by endothelial cells of PAMAM, indicating that the transport across a leaky BBB due to focal brain ischemia would be facilitated. Next, the functionalized dendrimers were tested in contact with red blood cells showing no haemolysis for the PEGylated PAMAM, in contrast to the unmodified dendrimer. Interestingly, the PEG-modified dendrimers reduced blood clotting, which may be an added beneficial function in the context of stroke. The optimized PAMAM formulation was intravenously administered in mice after inducing permanent focal brain ischemia. Twenty-four hours after administration, dendrimers could be detected in the brain, including in neurons of the ischemic cortex. Our results suggest that the proposed formulation has the potential for becoming a successful delivery vector for therapeutic application to the injured brain after stroke reaching the ischemic neurons.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Blood-brain barrier; Brain ischemia; Dendrimers; Drug delivery; In vivo; Nanomaterials; Nanomedicine; Poly(amido amine) PAMAM; Poly(ethylene glycol) PEG; Stroke

Mesh:

Substances:

Year:  2018        PMID: 30308255     DOI: 10.1016/j.jconrel.2018.10.006

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  14 in total

1.  The MEK 1/2 inhibitor PD98059 exhibits synergistic anti-endometrial cancer activity with paclitaxel in vitro and enhanced tissue distribution in vivo when formulated into PAMAM-coated PLGA-PEG nanoparticles.

Authors:  Kanawat Wiwatchaitawee; Aml I Mekkawy; Juliana C Quarterman; Youssef W Naguib; Kareem Ebeid; Sean M Geary; Aliasger K Salem
Journal:  Drug Deliv Transl Res       Date:  2021-10-11       Impact factor: 5.671

Review 2.  Enhancement of Therapies for Glioblastoma (GBM) Using Nanoparticle-based Delivery Systems.

Authors:  Kanawat Wiwatchaitawee; Juliana C Quarterman; Sean M Geary; Aliasger K Salem
Journal:  AAPS PharmSciTech       Date:  2021-02-11       Impact factor: 4.026

Review 3.  Biomaterials to Neuroprotect the Stroke Brain: A Large Opportunity for Narrow Time Windows.

Authors:  Daniel González-Nieto; Rocío Fernández-Serra; José Pérez-Rigueiro; Fivos Panetsos; Ricardo Martinez-Murillo; Gustavo V Guinea
Journal:  Cells       Date:  2020-04-26       Impact factor: 6.600

Review 4.  Breaking Barriers: Bioinspired Strategies for Targeted Neuronal Delivery to the Central Nervous System.

Authors:  Ana P Spencer; Marília Torrado; Beatriz Custódio; Sara C Silva-Reis; Sofia D Santos; Victoria Leiro; Ana P Pêgo
Journal:  Pharmaceutics       Date:  2020-02-23       Impact factor: 6.321

Review 5.  Nanocarriers for Stroke Therapy: Advances and Obstacles in Translating Animal Studies.

Authors:  Syed Abdullah Alkaff; Krishna Radhakrishnan; Anu Maashaa Nedumaran; Ping Liao; Bertrand Czarny
Journal:  Int J Nanomedicine       Date:  2020-01-21

Review 6.  Recent advances in the development of nanomedicines for the treatment of ischemic stroke.

Authors:  Xing Tian; Taojian Fan; Wentian Zhao; Ghulam Abbas; Bo Han; Ke Zhang; Nan Li; Ning Liu; Weiyuan Liang; Hao Huang; Wen Chen; Bing Wang; Zhongjian Xie
Journal:  Bioact Mater       Date:  2021-02-20

Review 7.  Physiological and Pathological Factors Affecting Drug Delivery to the Brain by Nanoparticles.

Authors:  Yamir Islam; Andrew G Leach; Jayden Smith; Stefano Pluchino; Christopher R Coxon; Muttuswamy Sivakumaran; James Downing; Amos A Fatokun; Meritxell Teixidò; Touraj Ehtezazi
Journal:  Adv Sci (Weinh)       Date:  2021-03-15       Impact factor: 16.806

8.  An Available Strategy for Nasal Brain Transport of Nanocomposite Based on PAMAM Dendrimers via In Situ Gel.

Authors:  Huichao Xie; Lingjun Li; Yue Sun; Yuzhen Wang; Shuang Gao; Yuan Tian; Xuemei Ma; Chengcheng Guo; Fumin Bo; Li Zhang
Journal:  Nanomaterials (Basel)       Date:  2019-01-24       Impact factor: 5.076

Review 9.  The Role of Natural Compounds and their Nanocarriers in the Treatment of CNS Inflammation.

Authors:  Bikram Khadka; Jae-Young Lee; Dong Ho Park; Ki-Taek Kim; Jong-Sup Bae
Journal:  Biomolecules       Date:  2020-10-01

Review 10.  Therapeutic Nanoparticles for the Different Phases of Ischemic Stroke.

Authors:  Sara Bernardo-Castro; Inês Albino; Ángela María Barrera-Sandoval; Francesca Tomatis; João André Sousa; Emanuel Martins; Susana Simões; Miguel M Lino; Lino Ferreira; João Sargento-Freitas
Journal:  Life (Basel)       Date:  2021-05-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.